Drugs Similar to BRIDION
SUGAMMADEX
Related medications based on brand, generic name, substance, active ingredients.
By Brand
Drugs with the same brand name or brand family
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure
By Generic Name
Drugs with the same generic name (different brands)
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure
By Substance
Drugs sharing the same substance name
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure
BRIDION (sugammadex) injection, for intravenous use, contains sugammadex sodium, a modified gamma cyclodextrin chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -Octakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G ,6 H -octathio- γ -cyclodextrin sodium salt (1:8) with a molecular weight of 2178.01. The structural formula is: BRIDION is supplied as a sterile, non-pyrogenic aqueous solution that is clear, colorless to slightly yellow-brown for intravenous injection only. Each mL contains 100 mg sugammadex, which is equivalent to 108.8 mg sugammadex sodium. The aqueous solution is adjusted to a pH of between 7 and 8 with hydrochloric acid and/or sodium hydroxide. The osmolality of the product is between 300 and 500 mOsmol/kg. BRIDION may contain up to 7 mg/mL of the mono OH-derivative of sugammadex [see Clinical Pharmacology (12.2) ] . This derivative is chemically designated as 6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -Heptakis-S-(2-carboxyethyl)-6 A ,6 B ,6 C ,6 D ,6 E ,6 F ,6 G -heptathio- γ -cyclodextrin sodium salt (1:7) with a molecular weight of 2067.90. The structural formula is: Chemical Structure Chemical Structure